ISB News

TCGA, ISB Researchers Identify Potential Drug Targets for Leading Form of Deadly Liver Cancer

June 19, 2017

Researchers in ISB’s Shmulevich Lab and their colleagues in The Cancer Genome Atlas Research Network performed the first large-scale, multi-platform analysis of hepatocellular carcinoma, the predominant form of liver cancer. Study was published on June 15, 2017, in the journal Cell.

3 Bullets:

  • Liver cancer is the second most common cause of death from cancer worldwide.
  • ISB researchers and colleagues from The Cancer Genome Atlas Research Network performed the first large-scale, multi-platform analysis of hepatocellular carcinoma, the predominant form of liver cancer.
  • Such integrated analyses enabled the identification of potential therapeutic targets and facilitated biological insights that would not have been possible otherwise.

READ THE SUMMARY AND PAPER

 

Related Articles

  • Reconstructing 'Ötzi' the Iceman’s last meal

    Members of the Moritz lab, as part of an international consortium centered in Bolzano Italy, reports this week in Cell, “Current Biology”, a multi-omic approach to identify the stomach contents and microbiome of the 5300 year old Mummy, Oetzi, the Iceman from the Oetzal Alps on the Austrian/Italian border.

    Read More
  • ISB’s Computational Teams Play Central Role in Completion of TCGA’s PanCancer Atlas Initiative

    ISB’s computational and bioinformatics teams played a central role in the completion of the PanCancer Atlas Initiative, the final phase of TCGA. The culmination of this work is being published in 27 papers this week across the Cell Press research journals, including “The Immune Landscape of Cancer” in Immunity.

    Read More
  • CRI, ISB, Sage Bionetworks Unveil Comprehensive Immunotherapy Tool

    Three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics announced the release of the Cancer Research Institute iAtlas, a comprehensive web-based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment.

    Read More
Show More Articles